Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Oct 1 JAZZ Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now?
Oct 1 IONS Ionis gets U.S. FDA fast track designation for its Alexander disease treatment
Oct 1 AYTU Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
Oct 1 INO INOVIO to Present at Upcoming Scientific Conferences
Oct 1 IONS Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Sep 30 INO Inovio Pharmaceuticals: Takes Another Torpedo But Keeps On Sailing
Sep 28 AYTU Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations
Sep 27 ONCO Crude Oil Rises; Onconetix Shares Spike Higher
Sep 27 ONCO Onconetix rallies after Altos Venture reports 32.5% stake
Sep 27 ONCO Dow Surges Over 100 Points; Costco Earnings Top Views
Sep 27 BNR Burning Rock CFO resigns
Sep 27 BNR Burning Rock Announces Changes to Management and Board of Directors
Sep 27 AYTU Q4 2024 Aytu Biopharma Inc Earnings Call
Sep 26 AYTU Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript
Sep 26 AYTU Aytu BioPharma files mixed offering
Sep 26 AYTU Aytu BioPharma FY GAAP EPS of -$2.86 misses by $0.37, revenue of $81M misses by $0.33M
Sep 26 AYTU Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
Sep 26 OPK ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Sep 25 AYTU Aytu BioScience Q4 Earnings Preview
Sep 25 OPK Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags